Mundipharma buys Infarco’s Cinfa unit

Mundipharma has deepened its biosimilars platform “beyond commercial excellence to development” by acquiring European developer and manufacturer Cinfa Biotech, gaining immediate access to the Spanish player’s Pelmeg (pegfilgrastim) biosimilar that was backed for a European marketing authorisation last month.